DiaMedica Therapeutics Inc Asset Resilience Ratio
DiaMedica Therapeutics Inc asset resilience ratio. DiaMedica Therapeutics Inc (DMAC) has an Asset Resilience Ratio of 87.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DiaMedica Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DiaMedica Therapeutics Inc (2010–2025)
Asset resilience ratio of DiaMedica Therapeutics Inc from 2010 to 2025. This chart shows how DiaMedica Therapeutics Inc's Asset Resilience Ratio has changed over time. Read how much debt does DiaMedica Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down DiaMedica Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DiaMedica Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $46.46 Million | 87.53% |
| Total Liquid Assets | $46.46 Million | 87.53% |
Asset Resilience Insights
- Very High Liquidity: DiaMedica Therapeutics Inc maintains exceptional liquid asset reserves at 87.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
DiaMedica Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare DiaMedica Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
DiaMedica Therapeutics Inc Asset Resilience Ratio by Year (2010–2025)
DiaMedica Therapeutics Inc asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for DiaMedica Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.09% | $44.24 Million | $61.37 Million | -16.64pp |
| 2024-12-31 | 88.73% | $41.12 Million | $46.34 Million | -0.55pp |
| 2023-12-31 | 89.28% | $48.35 Million | $54.16 Million | +5.62pp |
| 2022-12-31 | 83.66% | $28.77 Million | $34.40 Million | -5.05pp |
| 2021-12-31 | 88.70% | $40.41 Million | $45.55 Million | +17.17pp |
| 2020-12-31 | 71.54% | $20.10 Million | $28.09 Million | +27.41pp |
| 2019-12-31 | 44.13% | $4.00 Million | $9.05 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $18.34 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $1.80 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $1.87 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $2.91 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $3.85 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $6.33 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $9.08 Million | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more